Ipamorelin / CJC-1295 (no DAC)
GH secretagogue combo—short-acting CJC without DAC with ipamorelin.
In short
- Ipamorelin plus CJC-1295 without DAC — the canonical growth hormone secretagogue pairing.
- This is the one blend format with a genuine mechanistic basis: the two act on DIFFERENT receptors, and the combination produces a larger GH pulse than either alone.
- That synergy is documented for the drug classes (GHRH plus ghrelin receptor agonist) in endocrinology literature, though not for these specific products.
- Explicitly the no-DAC variant — half-life around 30 minutes rather than the several days of the DAC form.
- Prohibited at all times in sport under WADA class S2.
Structure
A blend of two peptides. See the Ipamorelin and CJC-1295 no DAC entries for their individual structures.
How it works
CJC-1295 without DAC is a modified GHRH(1-29) analogue acting on the pituitary GHRH receptor. Ipamorelin is a selective agonist at the growth hormone secretagogue receptor, the ghrelin receptor.
Because these are separate receptors on the same cells, stimulating both simultaneously produces a GH pulse larger than the sum of either alone. This is established pharmacology for the GHRH-plus-secretagogue combination generally, and it is why this pairing is the standard rather than an arbitrary vendor choice.
Ipamorelin's selectivity is what makes it the preferred partner over GHRP-6 or GHRP-2 — it achieves the ghrelin-receptor half without their cortisol, prolactin, and appetite effects.
What the research shows
GH release from the combination is well supported at the class level.
What is not established is the step after that: no controlled trial shows that repeatedly raising GH pulses in a healthy adult produces the body composition or recovery outcomes people use this for. Raising GH is demonstrated; benefiting from it is not.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
No published dosing data for this compound.
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported, one to three times daily | 100 µg CJC-1295 no DAC with 200–300 µg ipamorelin | subcutaneous |
No study has tested this specific combination in humans. Whatever evidence exists belongs to the individual components, tested individually. A pre-mixed vial fixes the ratio between components at whatever the vendor chose. You can change the total volume you draw, but you cannot change the proportions — so if one component suits you at a different relative amount, a blend cannot express that. Buying components separately costs more vials and buys back that control. The commonly cited "100/100" or "1:1" convention is community practice, not a studied ratio. Both components are short-acting, so timing matters more here than in most blends — doses are usually taken away from food, since elevated glucose and insulin blunt GH release.
Handling and storage
Supplied as a lyophilised powder requiring reconstitution with bacteriostatic water. The powder is comparatively stable; once reconstituted it is refrigerated and used within weeks. Track the date you reconstitute each vial — the Inventory section does this, and it is the difference between knowing a vial is three weeks old and guessing.
Subcutaneous injection, commonly before sleep to coincide with the natural nocturnal GH pulse, and away from food.
Unlike most blends, the two components here have compatible half-lives and schedules, so a pre-mix is genuinely convenient rather than a compromise.
Side effects
Reported: injection-site reactions, flushing, a head-rush shortly after injection, water retention, and tingling in the extremities.
Ipamorelin's selectivity means the cortisol, prolactin, and hunger effects of the older GHRPs are largely absent.
Class effects of raising GH apply — joint discomfort, carpal tunnel symptoms, and reduced insulin sensitivity — though brief pulses are less associated with these than sustained elevation.
No long-term human safety data exists for this combination.
Combinations
Running components together makes attribution impossible in both directions. If something improves you cannot tell which component did it, and if something goes wrong you cannot tell which one to stop. Blends are convenient and they are also the format that teaches you least about your own response.
That said, this is the blend where combining is the point rather than a compromise — the two mechanisms genuinely differ, and separating them would defeat the purpose.
Research status
The GHRH-plus-secretagogue synergy is real endocrinology, described in the components' own entries.
Neither specific product has a completed clinical trial, and the combination as sold has never been studied.
Legal status
Neither component is approved in any jurisdiction. Sold for research use only. GH secretagogues and releasing factors appear on the FDA list of substances presenting significant risks for compounding.
WADA status
PROHIBITED AT ALL TIMES under WADA class S2 — growth hormone secretagogues, their releasing factors and mimetics are explicitly named. Any tested athlete should treat this as an anti-doping violation.
Conclusion
This is the most mechanistically justified blend in the library — two different receptors, genuine synergy, compatible pharmacokinetics.
What it does not have is evidence that the resulting GH pulses produce anything you want. The pharmacology is sound up to the point where the outcomes would have to be measured, and nobody has measured them.
Sources
Track your own Ipamorelin / CJC-1295 (no DAC) protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.